|
|
||||||||
1Lawson Health Research Institute, AC Burton Vascular Biology Laboratory, Respirology, London Health Sciences Centre, London N6A 4G5; 2Department of Physiology and Pharmacology, University of Western Ontario, London, Ontario, Canada, N6A 5C1; and 3National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina 27709
Submitted 14 August 2003 ; accepted in final form 29 January 2004
Recently, we demonstrated that pulmonary CYP2J4 content, a prominent source of EETs and HETEs formation in rat lungs, is reduced in pneumonia. Therefore, the purpose of this study was to determine the role of iNOS-derived NO in reduced pulmonary CYP2J4 protein content and decreased CYP metabolites in pneumonia. Rats were randomized to control, control plus 1400W (iNOS inhibitor), pneumonia, and pneumonia plus 1400W groups. Pseudomonas organisms were injected into lungs of pneumonia rats. At 40 h after surgery, rats were treated with either saline or 1400W for 4 h before death. Venous plasma samples were obtained for measuring nitrites/nitrates (NOx). There was no significant effect of 1400W on blood pressure measured in control or pneumonia rats, whereas 1400W reduced the elevated plasma NOx levels in pneumonia rats by half. CYP primary metabolites of AA formed at significantly lower rates in pulmonary microsomes from pneumonia rats compared with control rats. Treatment of pneumonia rats with 1400W resulted in a significant increase in the rate of formation of pulmonary EETs and
-terminal HETEs compared with untreated pneumonia rats. The reduction in CYP2J4 protein content in pneumonia lung microsomes was also partially prevented by 1400W. Therefore, excess NO from iNOS decreases the pulmonary production of EETs and
-HETEs in acute pneumonia. Inhibition of iNOS restores CYP2J4 protein content and CYP activity in acute pneumonia, indicating an important NO-CYP interaction in pulmonary responses to infection. We speculate CYP2J4 and its AA metabolites are involved in the modulation of pulmonary function in health and disease.
inflammation; CYP2J4 protein content; CYP450 activity assays; epoxyeicosatrienoic acids and
-terminal hydroxyeicosatetraenoic acids; 1400W
This article has been cited by other articles:
![]() |
J. J. Iliff, R. Wang, D. C. Zeldin, and N. J. Alkayed Epoxyeicosanoids as mediators of neurogenic vasodilation in cerebral vessels Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1352 - H1363. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |